Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
932 Leser
Artikel bewerten:
(2)

Nasdaq Nordic: Nasdaq Stockholm Welcomes Prostatype Genomics to Nasdaq First North Growth Market

Stockholm, November 3, 2020 - Nasdaq (Nasdaq: NDAQ) announces that trading in
Prostatype Genomics AB's shares (short name PROGEN) commences today on Nasdaq
First North Growth Market. The company belongs to the Health care sector.
Prostatype Genomics is the 53rd company to be admitted to trading on Nasdaq's
Nordic markets* in 2020. 

Prostatype Genomics is a heath care company focusing on the issue of prostate
cancer. The company has developed a system that provides the patient and doctor
with supplementary information prior to making a decision on whether or not
treatment is necessary. Prostatype gives new prerequisites for reaching a
clearer answer. Through gene analysis, the patient and doctor receive a measure
indicating how aggressive or non-aggressive the cancer is. It provides a better
basis when faced with the often difficult treatment decision. 

"Taking the step to the Nasdaq First North Growth Market is an important
milestone in the company's history," said Fredrik Persson, CEO of Prostatype
Genomics. "The listing gives us new possibilities, for example how to ensure
our future growth. We have our focus set on the future and look forward to
launching our product to important markets in the coming years. There is a
great need to be able to diagnose and prognosticate prostate cancer, the most
common cancer type among men in the Western world, which is also increasing
globally. With our unique test kit, Prostatype, we will play a large role in
improving quality of life for patients with prostate cancer, while lowering
costs for the health care system." 

"We are pleased to welcome Prostatype Genomics to the Nasdaq family as they
list on our First North Growth Market," said Adam Kostyál, Head of European
Listings at Nasdaq. "We congratulate Prostatype Genomics on its successful
listing and look forward to supporting the company on its continued journey as
a member of the Nasdaq family." 

Prostatype Genomics has appointed Svensk Kapitalmarknadsgranskning AB as
Certified Adviser. 

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki,
Nasdaq Iceland and Nasdaq Stockholm 

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital
markets and other industries. Our diverse offering of data, analytics, software
and services enables clients to optimize and execute their business vision with
confidence. To learn more about the company, technology solutions and career
opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. 

Nasdaq Media Contact

Rebecka Wulfing
+46 73 449 7122
rebecka.wulfing@nasdaq.com
Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.